Ventyx Biosciences price target raised to $65 from $50 at Evercore ISI

Evercore ISI analyst Joshua Schimmer raised the firm’s price target on Ventyx Biosciences to $65 from $50 and keeps an Outperform rating on the shares following what the firm called "another masterful presentation pulling together disparate data points to provide a clear and crisp outlook across its portfolio." While stating that it will be "keeping a close watch on" other assets and indications, for now the firm is only increasing its S1P1 estimates for UC, driving its increased price target.